1. The potential health gain and cost savings of improving adherence in chronic myeloid leukemia.
- Author
-
Ector GICG, Govers TM, Westerweel PE, Grutters JPC, and Blijlevens NMA
- Subjects
- Cost-Benefit Analysis, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive diagnosis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive therapy, Leukemia, Myeloid, Chronic-Phase drug therapy, Leukemia, Myeloid, Chronic-Phase epidemiology, Netherlands epidemiology, Patient Outcome Assessment, Quality of Health Care, Cost Savings, Guideline Adherence, Health Care Costs, Leukemia, Myelogenous, Chronic, BCR-ABL Positive epidemiology, Medication Adherence
- Abstract
Healthcare costs are rising due to an increase in chronic diseases, including chronic myeloid leukemia (CML) due to improved survival. In CML care, patient adherence and physician adherence are key elements. We assessed the potential health gain and cost savings when both are improved, using a decision analytic model that integrated various sources of evidence. The current situation was compared to a theoretical situation in which either patient or physician adherence is improved, in terms of costs and quality-adjusted life years (QALYs). Current patient adherence rate is 74%, improvement to 100% resulted in 0.1031 QALYs gained and a saving of €17,509 per patient over a 25-year period. Improving physician adherence from 72% to 100%, resulted in 0.0380 QALYs and €7606. Enhancement of either adherence results in substantial health gain and cost savings. Regarding the rising healthcare costs, new strategies should focus on improving adherence to keep healthcare affordable in the future.
- Published
- 2019
- Full Text
- View/download PDF